Heart failure & cardiomyopathies
Long-Term Tafamidis Efficacy in Patients with Transthyretin Amyloid Cardiomyopathy by Baseline Left Ventricular Ejection Fraction
Authors' conclusion
Early initiation of tafamidis is associated with reduced mortality in patients with ATTR-CM, irrespective of initial LVEF value.
Study context
- Population
- Patients with ATTR-CM, by baseline left ventricular ejection fraction (LVEF) (<50% or ≥50%)LVEF <50% n = 177
- Comparison
- Continuous tafamidis vs delayed tafamidis
- Primary endpoint
- All-cause mortality (death, heart transplant or cardiac mechanical assist device implantation)
- Follow-up
- End (median 60-64 months)
Methodological detailsphase 3, subgroup analysis by baseline LVEF
- Phase 3
- Subgroup analysis by baseline LVEF
Primary result
As reported in the abstract
All-cause mortality by baseline LVEF · median 60-64 months
Continuous tafamidis vs Delayed tafamidisHazard ratio (95% CI)P value
LVEF <50% (88 tafamidis, 89 placebo)
0.53(0.367–0.758)
P < 0.001LVEF ≥50% (85 tafamidis, 86 placebo)
0.53(0.344–0.818)
P < 0.01Further findings
Supportive outcomes (shorter follow-up)
- Consistent with mortality findings
Original publication
Long-Term Tafamidis Efficacy in Patients with Transthyretin Amyloid Cardiomyopathy by Baseline Left Ventricular Ejection Fraction. Eur J Heart Fail. Published 26 June 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →